[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628278":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Group of Stapokibart Injection",null,[12],"Biological: Stapokibart",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Stapokibart","subcutaneous injection",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[26],{"facility":27,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Beijing Tongren Hospital, CMU","Beijing","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100628278","a-prospective-study-of-stapokibart-injection-in-patients-with-seasonal-allergic-rhinitis-sar-100628278",false,"NCT07459556","A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)","A Prospective Study of Stapokibart Injection in Patients With SAR","Inclusion Criteria:\n\n* Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.\n* Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Participants currently or plan participating in any interventional clinical trial.\n* Participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.","ALL","18 Years",{"count":51,"type":52},400,"ESTIMATED","OBSERVATIONAL","This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.",[56],"SAR","NOT_YET_RECRUITING","2026-03-05",{"date":60,"type":61},"2026-03-09","ACTUAL",{"date":63,"type":52},"2026-03",{"date":65,"type":52},"2028-02",{"name":5,"class":6},1]